Total (n=125)No itching (n=96)Itching (n=29)P
Age (SD), years52.2 (10.1)52.3 (10.1)51.6 (10.2)0.73
Women, n (%)62 (49.6%)49 (51.0%)13 (44.8%)0.56
BMI (SD), kg/m228.3 (4.3)28.0 (4.0)29.4 (4.9)0.12
Smoking, n (%)19 (15.2%)14 (14.6%)5 (17.2%)0.73
Dis.dur. (SD), years8.9 (6.7)9.1 (6.7)8.0 (6.9)0.42
CRP (SD), mg /L4.8 (8.5)4.4 (8.5)6.1 (8.5)0.37
TJC68 (SD)9.70 (11.07)9.21 (10.32)11.39 (13.41)0.36
SJC66 (SD)0.57 (0.99)0.56 (1.00)0.61 (0.96)0.84
MASES (SD)2.9 (3.1)2.5 (2.9)4.0 (3.7)0.02
IGA (SD), (VAS 0-100)14.0 (11.7)12.9 (10.2)17.8 (15.4)0.12
PGA (SD), (VAS 0-100)35.3 (24.2)30.5 (22.6)50.9 (22.8)<0.01
Pain (SD), (VAS 0-100)33.4 (23.4)28.6 (21.3)49.1 (23.6)<0.01
Fatigue (SD), (VAS 0-100)45.1 (32.0)40.3 (31.7)61.0 (28.1)<0.01
MHAQ (SD), (0-3)0.40 (0.35)0.35 (0.32)0.58 (0.39)<0.01
PASI (SD), (0-72)2.4 (3.5)1.9 (3.2)4.1 (4.1)0.01
DLQI (SD), (0-30)3.5 (3.6)2.2 (2.3)7.9 (3.9)<0.01
15D (SD), (0-1)0.84 (0.09)0.86 (0.09)0.80 (0.08)<0.01
bDMARDs, n (%)43 (34.7%)33 (34.7%)10 (34.5%)0.98
csDMARDs, n (%)73 (58.4%)61 (63.5%)12 (41.4)0.03
  • Dis.dur.: disease duration

  • In univariate analysis itching was found to be associated with impaired HRQoL assessed by 15D but not in adjusted analysis. In a regression model adjusting for age, gender, BMI and including variables with p<0.2 in univariate analysis (MASES enthesitis score, investigator [IGA] and patients global assessment [PGA], fatigue, pain, MHAQ, Psoriasis Area Severity Index [PASI] score and itching and treatment), only female gender, PASI score and itching were independently associated with reduced skin HRQoL.